Novavax, Inc. (NVAX) compared with its closest peers (RXRX, MAZE, VIR, INBX, MGTX). Peer set by Business model: Biotech (Clinical / Commercial-Stage); 10 closest by market cap; US-domiciled. First-party data.
| Company | Market Cap | P/E |
|---|---|---|
| Recursion Pharmaceuticals, Inc. (RXRX) | $1.77B | -2.8 |
| Maze Therapeutics, Inc. (MAZE) | $1.61B | -13.6 |
| Vir Biotechnology, Inc. (VIR) | $1.55B | -1.9 |
| Inhibrx Biosciences, Inc. (INBX) | $1.46B | -8.7 |
| MeiraGTx Holdings plc (MGTX) | $1.39B | 79.3 |
| Cullinan Therapeutics, Inc. (CGEM) | $1.38B | — |
| Replimune Group, Inc. (REPL) | $1.32B | -2.3 |
| Monte Rosa Therapeutics, Inc. (GLUE) | $1.26B | -34.1 |
| Vor Biopharma Inc. (VOR) | $1.25B | -0.2 |
| Sana Biotechnology, Inc. (SANA) | $1.12B | -4.2 |
| Sector P/E (Healthcare) | 21.6 |
| Industry P/E (Pharmaceutical Products) | 17.2 |
NVAX overview · NVAX earnings · NVAX financials · NVAX KPIs · NVAX investor relations · NVAX ownership · NVAX filings
Data sourced from U.S. SEC EDGAR filings and market data. Not personalized investment advice.